Cite
HARVARD Citation
Wang, Y. et al. (2021). A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome. Journal of medical economics. pp. 1503-1515. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Wang, Y. et al. (2021). A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome. Journal of medical economics. pp. 1503-1515. [Online].